Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya

Bulletin of the World Health Organization

Volumn 79, Issue 5, 2001, Pages 388-393

  Moore, Elinore ^a   O'Flaherty, Deidre ^a   Heuvelmans, Hans ^a   Seaman, Jill ^a   Veeken, Hans ^a   De Wit, Sjoukje ^a   Davidson, Robert N ^b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

Antimony sodium gluconate therapeutic use; Comparative study; Drug evaluation; Drugs, Generic therapeutic use; Kenya (source: MeSH); Leishmaniasis, Visceral drug therapy

Indexed keywords

GENERIC DRUG; STIBOGLUCONATE SODIUM;

COMPARATIVE STUDY; DISEASE CONTROL; LEISHMANIASIS; SODIUM;

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; DRUG SCREENING; EVALUATION; FOLLOW UP; HUMAN; KENYA; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; RELAPSE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG EVALUATION; DRUGS, GENERIC; FEMALE; HUMANS; KENYA; LEISHMANIASIS, VISCERAL; MALE; TREATMENT OUTCOME;

KENYA;

EID: 0035000480     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Franco MA et al. Antimony oxidation states in antileishmanial drugs. American Journal of Tropical Medicine and Hygiene, 1995, 52: 435-437.
2. Sundar S et al. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. American Journal of Tropical Medicine and Hygiene, 1998, 59: 139-143.
3. Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treatment Reports, 1978, 62:1037-1040.
4. Pocock SJ. Clinical trials: a practical approach. London, John Wiley & Sons, 1983.
5. Manual on visceral leishmaniasis control. Geneva, World Health Organization, 1996 (unpublished document WHO/LEISH/96.40).
6. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clinical Infectious Diseases, 1997, 24: 684-703.
7. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. American Journal of Tropical Medicine and Hygiene, 1992, 46: 296-306.
8. Seaman J et al. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. Journal of Infectious Diseases, 1993, 168: 715-720.
9. Berman JD, Grogl M. Leishmania mexicana: chemistry and biochemistry of sodium stibogluconate (Pentostam®). Experimental Parasitology, 1988, 67: 96-103.
10. Roberts WL, Rainey PM. Antileishmanial activity of sodium stibogluconate fractions. Antimicrobial Agents and Chemotherapy, 1993, 37: 1842-1846.
11. Chowdhury S et al. Positive response to sodium antimony gluconate administration in visceral leishmaniasis seropositive patients. American Journal of Tropical Medicine and Hygiene, 1991, 44: 390-393.